Baricitinib in juvenile idiopathic arthritis: an international, phase 3, randomised, double-blind, placebo-controlled, withdrawal, efficacy, and safety trial. (2023)
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1016/s0140-6736(23)00921-2
PubMed Identifier: 37423231
Publication URI: http://europepmc.org/abstract/MED/37423231
Type: Journal Article/Review
Volume: 402
Parent Publication: Lancet (London, England)
Issue: 10401
ISSN: 0140-6736